In concordance with previous results, the ORR was significantly associated with PD-L1 expression (100% vs. 68.8%; p = 0.048) and DNA damage repair-related mutations (95.0% vs. 55.6%; p = 0.002) in tumor samples, again underlining the potential benefit of enrichment of patients based on their molecular profile to increase the efficacy of the treatment. The gene discussed is CD274; the disease is neoplasm.